Aura Biosciences, INC

Aura Biosciences has appointed Dr. Jeremy Bender to its Board of Directors, effective July 7, 2026, to bolster its strategic and operational capabilities.

Aura Biosciences stockholders elected two Class II directors and ratified the appointment of Ernst & Young LLP as the independent auditor for 2026.

Aura Biosciences has completed a public offering of common stock and pre-funded warrants, raising approximately $280.8 million in net proceeds.

Aura Biosciences announced an agreement to repurchase up to 6,922,870 shares of its common stock from Matrix Capital Management Master Fund, LP, funded by proceeds from an upcoming equity offering.

Aura Biosciences announced the appointment of Natalie Holles as CEO and President, succeeding founder Elisabet de los Pinos, as the company's Phase 3 CoMpass trial nears enrollment completion.

Aura Biosciences accelerated enrollment in its Phase 3 CoMpass trial, guided mid-2026 completion and 2H 2027 topline data, reported a wider FY25 net loss, and affirmed cash runway into Q1 2027.

Aura Biosciences reports increased R&D spend and net losses in Q3 2025, driven by clinical trial progression, while securing significant capital to extend its operational runway into H1 2027.

Aura Biosciences reports increased R&D spend and net losses in Q2 2025, fueled by progress in its lead oncology programs and a successful $69.9 million follow-on offering extending its cash runway into H1 2027.

Aura Biosciences reports a net loss of $27.5 million for Q1 2025, focusing on the development of bel-sar and expansion into new oncology indications.

Aura Biosciences, a clinical-stage biotech company, reported its third quarter 2024 financial results, highlighting progress in its bel-sar clinical trials and ongoing research and development efforts.

Aura Biosciences reports a net loss of $40 million for the first half of 2024, while advancing its bel-sar clinical programs.

Aura Biosciences reports a net loss of $19.7 million for the first quarter of 2024, while advancing its bel-sar clinical trials across multiple oncology indications.

Aura Biosciences reports a wider 2025 net loss, substantial doubt about going concern, active late‑stage bel-sar program under SPA, and recent/warranted financings to extend runway.

Aura Biosciences files its 10-K, reporting a net loss for 2024 while highlighting the ongoing Phase 3 trial of Bel-Sar and its potential across multiple oncology indications.

Aura Biosciences has filed an amendment to its annual report to update executive compensation details and beneficial ownership information.

Aura Biosciences' 10-K filing outlines the company's registered securities, registration rights, anti-takeover measures, and other corporate governance details.

Aura Biosciences Director Jeremy Bender acquired 30,000 shares of common stock through an RSU award and was granted an option to purchase 60,000 shares.

Aura Biosciences reports a Form 4 filing detailing the acquisition of common stock by Conor Kilroy, Chief Legal Officer and Secretary.

Aura Biosciences reports that Chief Financial and Business Officer Anthony S. Gibney sold shares to cover tax withholding obligations upon vesting of restricted stock units.

Aura Biosciences Director Teresa Marie Bitetti acquired 15,000 restricted stock units and a stock option for 30,000 shares.

Aura Biosciences Director Sapna Srivastava acquired 15,000 restricted stock units and was granted 30,000 stock options.

Aura Biosciences Director Antony C. Mattessich acquired 15,000 shares of common stock and was granted 30,000 stock options.

Aura Biosciences is holding a special meeting on August 5, 2026, to vote on increasing authorized shares and amending its 2021 Stock Option and Incentive Plan.

Aura Biosciences, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 11, 2026.

Aura Biosciences has scheduled its annual stockholder meeting for June 17, 2025, and is providing proxy materials for voting on key proposals, including the election of directors and ratification of the company's auditor.

Aura Biosciences announces its 2025 Annual Meeting of Stockholders to be held virtually on June 17, 2025, covering director elections and auditor ratification.

Aura Biosciences amends its proxy statement for the 2024 annual meeting to update disclosures related to executive and director compensation, including changes to named executive officers and corrections to option award calculations.

Aura Biosciences announces its 2024 Annual Meeting of Stockholders to be held virtually on June 20, 2024, featuring proposals for director elections, officer exculpation amendment, and auditor ratification.

Aura Biosciences, Inc. has filed an exit amendment to its Schedule 13D, reporting the repurchase of 6,922,870 shares of common stock by the issuer from Matrix Fund.

Matrix Capital Management Company LP and David E. Goel have filed an amended Schedule 13D, disclosing a beneficial ownership of 11.17% in Aura Biosciences, Inc. and confirming a 90-day lock-up agreement following the company's recent 2025 Offering.

TCG Crossover and Chen Yu have filed a Schedule 13G reporting a 9.9% beneficial ownership stake in Aura Biosciences, Inc.

Frazier Life Sciences entities filed an amended Schedule 13G, disclosing their beneficial ownership in Aura Biosciences, Inc. as of December 31, 2025.

BlackRock, Inc. has reported a 5.4% beneficial ownership stake in Aura Biosciences Inc., holding 3,336,027 shares of common stock.

Frazier Life Sciences funds and affiliates have filed an amended Schedule 13G, detailing their beneficial ownership in Aura Biosciences, Inc. common stock.

Suvretta Capital Management, Averill Master Fund, and Aaron Cowen disclose increased beneficial ownership in Aura Biosciences, Inc., reaching up to 7.6% of common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a reduction in its beneficial ownership stake in Aura Biosciences Inc. to 4.9% of common stock.